Share
PrintBradley Ozenberger, Ph.D.
Ph.D. University of Missouri, 1988
(301) 496-7531
(301) 480-2770
Room 4076, MSC 9305
Rockville, MD 20892-9305
Facilitating genomic research that will eventually help patients in the clinic motivates Dr. Bradley A. Ozenberger. One way he is already doing this is by administering The Cancer Genome Atlas (TCGA) program, a major effort by the National Human Genome Research Institute (NHGRI) and the National Cancer Institute (NCI) to generate comprehensive catalogs of the genetic changes underlying all major cancers.
In his new role as deputy director of the Division of Genomic Medicine in NHGRI's extramural research program, Dr. Ozenberger will begin to focus on moving discoveries from projects such as TCGA to healthcare applications.
"I'm excited to be selected for this position and prepared to guide the deployment of NHGRI initiatives in the nascent area of Genomic Medicine," Dr. Ozenberger said. "The new structure will give staff increased flexibility and enhanced support to achieve our goals as laid out in last year's strategic plan."
In addition to his TCGA responsibilities, Dr. Ozenberger oversees the Clinical Sequencing Exploratory Research (CSER) at NHGRI. This new program, part of NHGRI's Large Scale Sequencing Program, funds multi-disciplinary research on both the technological and psychosocial challenges in bringing powerful genomic sequencing approaches to the care of individual patients.
Dr. Ozenberger also contributes to the development of National Institutes of Health (NIH) policies for data access and protection of genetic research participant privacy.
Prior to joining NIH in 2003, Dr. Ozenberger was a senior investigator and team leader at Wyeth Pharmaceuticals in Princeton, NJ. His academic training includes a B.S. in biology from the University of Missouri in Columbia, and a Ph.D. in medical microbiology from the University of Missouri School of Medicine awarded in 1988, and a post-doctoral fellowship in the Department of Biology at Yale University.
Last Updated: October 1, 2012
